Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Peer Review reports

Original Submission
7 Oct 2015	Submitted	Original manuscript
7 Nov 2015	Reviewed	Reviewer Report - Yusuke Okuma
8 Nov 2015	Reviewed	Reviewer Report - Chang-Hsien Lu
8 Dec 2015	Author responded	Author comments - Victor Lee
Resubmission - Version 2
8 Dec 2015	Submitted	Manuscript version 2
22 Jan 2016	Author responded	Author comments - Victor Lee
Resubmission - Version 3
22 Jan 2016	Submitted	Manuscript version 3
6 Feb 2016	Author responded	Author comments - Victor Lee
Resubmission - Version 4
6 Feb 2016	Submitted	Manuscript version 4
Publishing
17 Feb 2016	Editorially accepted
24 Feb 2016	Article published	10.1186/s12885-016-2201-9

Back to article page